Viewing nowHeart Van Tablet 80mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Light Pharmaceuticals Co., Ltd.

MFDS item code 202001399 · Approved 2020.02.27 · Insurance code 690302380
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to control blood pressure in patients with essential hypertension and to improve symptoms in heart failure patients (NYHA class II to IV) who are intolerant to ACE inhibitors. Additionally, it helps reduce the risk of mortality in patients with left ventricular dysfunction following myocardial infarction. Due to its effectiveness for various cardiovascular diseases, it is actively used to manage the patient's condition.
* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily, and the dose should be increased over several weeks, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more daily is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension — Children and adolescents under 18 years: Safety and efficacy have not been established. 6. Pediatric patients — Children and adolescents under 18 years: Safety and efficacy have not been established.
This medication can cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, thus it must be discontinued immediately upon confirmation of pregnancy. Women who are pregnant, potentially pregnant, or nursing should not use this medication. Patients with severely impaired liver function, certain liver diseases, and severe renal impairment should not take this medication. Patients with a history of angioedema or those who experienced angioedema symptoms with ACE inhibitors or angiotensin II receptor antagonists should also avoid this medication. Elderly patients, those with elevated serum potassium levels, and patients with mild to moderate liver impairment should adjust the dosage and use caution. Blood pressure may drop sharply, so particular caution is needed when starting the treatment or increasing the dosage, and if symptoms of hypotension occur, medical consultation should be sought immediately. This medication may interact with other blood pressure medications or diuretics, including potassium-sparing diuretics, so it is essential to inform your healthcare provider of any other medications being taken. Symptoms such as dizziness or drowsiness may occur, hence caution is needed when driving or operating machinery. Possible adverse reactions during use include headache, dizziness, fatigue, cough, and dyspepsia; if serious symptoms arise, immediate notification to a healthcare provider is required. Safety and efficacy in pediatric patients under 18 years have not been established, hence it is advisable not to use this medication. In case of overdose, hypotension, decreased consciousness, and other symptoms may occur; therefore, emergency treatment should be sought immediately, and self-treatment should be avoided. Store this medication out of reach of children, taking care not to transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a well-sealed container to prevent air or moisture ingress. Additionally, it is important to keep the medication at a cool place below 30 degrees Celsius to maintain its effectiveness.
Pink round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Light Pharmaceuticals Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.